Silence Therapeutics (SLN) Shares Outstanding (Weighted Average) (2018 - 2026)

Silence Therapeutics has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $141.7 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $141.7 million, changed 0.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $141.7 million (changed 0.02% YoY), and the FY2025 annual result was $141.7 million, up 2.12% from the prior year.
• Shares Outstanding (Weighted Average) came in at $141.7 million for Q1 2026 at Silence Therapeutics, roughly flat from $141.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $141.7 million in Q1 2026 to a low of $113.3 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $141.2 million (2024), against an average of $137.1 million.
• Across the five-year window, Shares Outstanding (Weighted Average) decreased 5.52% in 2022 and grew 21.91% in 2023, its largest moves.
• Silence Therapeutics' Shares Outstanding (Weighted Average) stood at $113.3 million in 2022, then gained by 21.91% to $138.1 million in 2023, then increased by 0.46% to $138.8 million in 2024, then increased by 2.12% to $141.7 million in 2025, then rose by 0.01% to $141.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $141.7 million (Q1 2026), $141.7 million (Q4 2025), and $141.7 million (Q3 2025), per Business Quant data.